NEW YORK (TheStreet) -- It has been a roller-coaster ride for the S&P 500 during the last week, falling one day and gaining on the other. The index has lost 1.4% during the past week, followed by a 0.8% drop in Dow Jones and a 0.2% decline in India's Nifty Index. Among other emerging markets, Shanghai Composite Index gained 0.6% while Brazil's Bovespa inched up 0.2%.We list a few ADRs that have outperformed both the U.S. and domestic markets during this period. Synutra International ( SYUT) gained 18% during the last week. The company is a China-based producer, marketer and seller of nutritional products for infants, children and adults. As of March 31, 2010, the company's network is comprised of more than 540 independent distributors and more than 1,000 independent sub-distributors who sell its products in more than 71,000 retail outlets. On June 10, the company reported its results for the fourth quarter and full year 2010. Net sales during the fourth quarter increased 13.4% to $82.4 million, while the company swung to a net profit of 17 cents per share compared to a loss in the same period a year ago. Oppenheimer & Co. rated the stock a buy with a price target of $27, implying an 11% upside above current levels. A-Power Energy Generation ( APWR) gained 17.7% during the past week. The company is engaged in providing onsite distributed power generation systems and micro power grids for industrial companies, primarily in the Peoples Republic of China and Southeast Asia. The stock rose on the back of first-quarter 2010 results, which were released yesterday. Revenues jumped 115.8% year-over-year to $67.3 million. Net income soared to 66 cents per share from 4 cents per share a year ago, while cash and cash equivalents increased to $220.4 million from $179.8 million at Dec. 31, 2009. The company raised its outlook that revenue for 2010 will reach $500 million and net income will reach $60 million, from previously announced annual guidance of $380 million in revenues and $45 million in net income. Oppenheimer & Co. rated the stock a buy with price target of $15, implying a 64% upside over current levels.
China Medical Technologies ( APWR) was up 17.1%. The company develops, manufactures and markets advanced immunodiagnostic and molecular diagnostic products. On June 4, the company reported revenue of $25.7 million during the fourth quarter ended 2009, a 2% increase sequentially. Moreover, the company swung to a net profit of 5 cents per share compared to a loss of 12 cents per share in the previous quarter. Going forward, the company expects revenue to be more than $25.6 million and earnings to be more than 26 cents per share for the first quarter 2010. The Company estimates the target quarterly revenue to increase in a range of 5% to 7% on a quarter-over-quarter basis during 2010. Other China gainers include Acorn International ( ATV - Get Report) (+9%), Semiconductor Manufacturing ( SMI - Get Report) (+5.6%) and Yingli Green Energy ( YGE) (+5.6%). Indian Healthcare major Dr. Reddy's Laboratories ( RDY - Get Report) gained 4.8% during the last week. On June 9, the company received a preliminary nod from U.S. Food and Drug Administration to launch the generic version of AstraZeneca's ( AZN - Get Report) Accolate, used to treat asthma. Among Brazil ADRs, BRF Brasil Foods SA ( BRFS - Get Report), a food company with a focus on the production and sale of poultry, pork, beef cuts, milk, dairy products and processed food products gained 5.9% during the period under review. On June 4, HSBC rated the stock an overweight with price target of $17.50, implying a 27% upside over current levels. Moreover, Braskem SA ( BAK), CPFL Energia SA ( CPL - Get Report) and Petroleo Brasileiro SA ( PBR - Get Report) gained 5.1%, 4.6% and 4.6%, respectively. According to Bloomberg, Petroleo Brasileiro plans to buy 5 billion barrels of government-owned oil reserves with new stock and raise as much as $25 billion from minority investors. The offering will help fund $220 billion of spending through 2014, the world's largest oil-industry investment plan.